Comparison of Natalizumab and Fingolimod on Clinical, Neuropsychological and MRI Measures in Patients with Relapsing Remitting Multiple Sclerosis

Trial Profile

Comparison of Natalizumab and Fingolimod on Clinical, Neuropsychological and MRI Measures in Patients with Relapsing Remitting Multiple Sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Fingolimod (Primary) ; Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Oct 2017 Results of patterns of regional gray matter and white matter atrophy (n=55) presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology
    • 23 Jun 2015 Results presented at the 1st Congress of the European Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top